Advertisement

Flow Cytometry in Myelodysplastic Syndromes

  • C. Alhan
  • T.M. Westers
  • G.J. Ossenkoppele
  • Arjan A. van de Loosdrecht
Chapter

Abstract

Maturation and differentiation of hematopoietic cells is a tightly controlled process, leading to highly conserved levels of antigen expression at different stages of development. In myelodysplastic syndromes (MDS), precursor cell formation is affected resulting in deviation from the normal level of antigen expression in the (im)mature myelo-monocytic, erythroid and megakaryocytic cell lineages. Flow cytometry can detect minimal aberrancies in the differentiation of myelo-monocytic cell populations by changes in antigen expression in BM of MDS patients that are otherwise not detected by morphology.

Since new therapeutic strategies are emerging for MDS, a more refined diagnostic and prognostic procedure is of importance. In this chapter the principles of flow cytometry in MDS and the value of flow cytometry for the diagnosis and prognosis of MDS will be discussed with emphasis on technical issues and aberrancies that can be detected.

Keywords

Paroxysmal Nocturnal Hemoglobinuria Myeloid Progenitor Ring Sideroblasts Flow Cytometric Study Growth Factor Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Alhan C et al (2009) Do peripheral blasts count in myelodysplastic syndromes? Leuk Res 33:209–211PubMedCrossRefGoogle Scholar
  2. 2.
    Arroyo JL et al (2004) Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. Hematol J 5:227–233PubMedCrossRefGoogle Scholar
  3. 3.
    Bennett JM et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199PubMedGoogle Scholar
  4. 4.
    Bowen KL, Davis BH (1997) Abnormal patterns of expression of CD16 (Flow cytometryR-III) and CD11b (CRIII) antigens by developing neutrophils in the bone marrow of patients with myelodysplastic syndrome. Lab Hematol 3:292–298Google Scholar
  5. 5.
    Brooimans RA et al (2008) Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination 1. Cytometry B Clin Cytom 76B:18–26Google Scholar
  6. 6.
    Cesana C et al (2008) Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. Leuk Res 32:1715–1723PubMedCrossRefGoogle Scholar
  7. 7.
    Cherian S et al (2005) Flow-cytometric analysis of peripheral blood neutrophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes. Am J Hematol 79:243–245PubMedCrossRefGoogle Scholar
  8. 8.
    Craig FE, Foon KA (2008) Flow cytometric immunophenotyping for hematologic neoplasms. Blood 111:3941–3967PubMedCrossRefGoogle Scholar
  9. 9.
    Del Canizo MC et al (2003) Immunophenotypic analysis of myelodysplastic syndromes. Haematologica 88:402–407PubMedGoogle Scholar
  10. 10.
    Della Porta MG et al (2006) Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 20:549–555PubMedCrossRefGoogle Scholar
  11. 11.
    Elghetany MT, Davis BH (2005) Impact of preanalytical variables on granulocytic surface antigen expression: a review. Cytometry B Clin Cytom 65:1–5PubMedGoogle Scholar
  12. 12.
    Feller N et al (2004) MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18:1380–1390PubMedCrossRefGoogle Scholar
  13. 13.
    Goardon N et al (2009) Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes. Haematologica 94:1160–1163PubMedCrossRefGoogle Scholar
  14. 14.
    Hellström-Lindberg E et al (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodyplastic syndromes: proposal for a predictive model. Br J Haematol 99:344–351PubMedCrossRefGoogle Scholar
  15. 15.
    Hellström-Lindberg E et al (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120:1037–1046PubMedCrossRefGoogle Scholar
  16. 16.
    Hellström-Lindberg E, Malcovati L (2008) Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol 45:14–22PubMedCrossRefGoogle Scholar
  17. 17.
    Holdrinet RS et al (1980) A method for quantification of peripheral blood admixture in bone marrow aspirates. Exp Hematol 8:103–107PubMedGoogle Scholar
  18. 18.
    Jaffe ES et al (2001) World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, LyonGoogle Scholar
  19. 19.
    Knipp S et al (2008) Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res 32:33–37PubMedCrossRefGoogle Scholar
  20. 20.
    Kussick SJ et al (2005) Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 124:170–181PubMedCrossRefGoogle Scholar
  21. 21.
    Lacronique-Gazaille C et al (2007) A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML. Haematologica 92:859–860PubMedCrossRefGoogle Scholar
  22. 22.
    Loken MR et al (1987) Flow cytometric analysis of human bone marrow: I. Normal erythroid development. Blood 69:255–263Google Scholar
  23. 23.
    Loken MR et al (2008) Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 32:5–17PubMedCrossRefGoogle Scholar
  24. 24.
    Loken MR et al (2008) Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry B Clin Cytom 76B:27–36Google Scholar
  25. 25.
    Lorand-Metze et al (2007) Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leuk Res 31:147–155CrossRefGoogle Scholar
  26. 26.
    Lorand-Metze et al (2008) The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes. Leuk Res 32:211–213CrossRefGoogle Scholar
  27. 27.
    Malcovati L et al (2005) Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 19:776–783PubMedCrossRefGoogle Scholar
  28. 28.
    Malcovati L et al (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23:7594–7603PubMedCrossRefGoogle Scholar
  29. 29.
    Matarraz S et al (2008) The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 22:1175–1183PubMedCrossRefGoogle Scholar
  30. 30.
    Matarraz S et al (2010) Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom 78:154–168PubMedGoogle Scholar
  31. 31.
    Maynadié M et al (2002) Immunophenotypic clustering of myelodysplastic syndromes. Blood 100:2349–2356PubMedCrossRefGoogle Scholar
  32. 32.
    Nakao S et al (2006) Clinical significance of a small population of paroxysmal nocturnal hemoglobinuria-type cells in the management of bone marrow failure. Int J Hematol 84:118–122PubMedCrossRefGoogle Scholar
  33. 33.
    Ogata K et al (2002) Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 100:3887–3896PubMedCrossRefGoogle Scholar
  34. 34.
    Ogata K et al (2006) Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 108:1037–1044PubMedCrossRefGoogle Scholar
  35. 35.
    Ogata K et al (2009) Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica 94:1066–1074PubMedCrossRefGoogle Scholar
  36. 36.
    Pirruccello SJ et al (2006) Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. Am J Clin Pathol 125:884–894PubMedCrossRefGoogle Scholar
  37. 37.
    Satoh C et al (2008) Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes. Leuk Res 32:699–707PubMedCrossRefGoogle Scholar
  38. 38.
    Satoh C et al (2009) Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes. Leuk Res 33:326–331PubMedCrossRefGoogle Scholar
  39. 39.
    Scott BL et al (2008) Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 112:2681–2686PubMedCrossRefGoogle Scholar
  40. 40.
    Stachurski D et al (2008) Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 32:215–224PubMedCrossRefGoogle Scholar
  41. 41.
    Sternberg A et al (2005) Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 106:2982–2991PubMedCrossRefGoogle Scholar
  42. 42.
    Stetler-Stevenson M et al (2001) Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98:979–987PubMedCrossRefGoogle Scholar
  43. 43.
    Subirá D et al (2008) Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or myeloproliferative disorders? Trans Res 151:240–245CrossRefGoogle Scholar
  44. 44.
    Swerdlow SH (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Press, SwitzerlandGoogle Scholar
  45. 45.
    Tehranchi R et al (2005) Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 106:247–253PubMedCrossRefGoogle Scholar
  46. 46.
    Terstappen LW et al (1992) Flow cytometric characterization of acute myeloid leukemia. Part II: phenotypic heterogeneity at diagnosis. Leukemia 6:70–80PubMedGoogle Scholar
  47. 47.
    Truong F et al (2009) The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. Leuk Res 33:1039–1046PubMedCrossRefGoogle Scholar
  48. 48.
    Valent P et al (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuke Res 31:727–736CrossRefGoogle Scholar
  49. 49.
    van de Loosdrecht AA et al (2008) Identification of distinct prognostic subgroups in low and intermediate-1 risk myelodysplastic syndromes by flow cytometry. Blood 111:1067–1077PubMedCrossRefGoogle Scholar
  50. 50.
    van de Loosdrecht AA et al (2009) Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 94:1124–1134PubMedCrossRefGoogle Scholar
  51. 51.
    van Lochem EG et al (2004) Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related and disease-induced shifts. Cytometry B Clin Cytom 60:1–13PubMedCrossRefGoogle Scholar
  52. 52.
    Wood BL (2007) Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukaemia. Clin Lab Med 27:551–575PubMedCrossRefGoogle Scholar
  53. 53.
    Wells DA et al (1998) Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. Am J Clin Pathol 110:84–94PubMedGoogle Scholar
  54. 54.
    Wells DA et al (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 102:394–403PubMedCrossRefGoogle Scholar
  55. 55.
    Westers TM et al (2010) Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 115:1779–1784PubMedCrossRefGoogle Scholar
  56. 56.
    Xu Y et al (2005) Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukaemia from reactive monocytosis. Am J Clin Pathol 124:799–806PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • C. Alhan
    • 1
  • T.M. Westers
    • 1
  • G.J. Ossenkoppele
    • 1
  • Arjan A. van de Loosdrecht
    • 1
  1. 1.Department of HematologyVU Institute for Cancer and Immunology, VU University Medical CenterAmsterdamThe Netherlands

Personalised recommendations